大脑作为容易出现局限性和转移性肿瘤的部位，一直是肿瘤学研究的关注焦点。脑胶质母细胞瘤（GBM）是最常见的侵袭性原发性脑肿瘤，占全球所有与癌症相关的死亡人数的4%。尽管有新的技术出现，但平均生存率仍为2年。生理屏障，如血脑屏障（BBB），阻止药物分子进入脑内。市场上大多数药物无法渗透血脑屏障以发挥最大的疗效，这也带来了一项重大挑战。本综述论文讨论了GBM以及抗癌药物输送的生理和生物屏障，跨越血脑屏障的药物输送策略，重点讨论了固体脂质纳米颗粒（SLNs）和纳米结构脂质载体（NLCs）及其在进行中的临床试验中的医学应用。过去几十年来，已经引入了具有各种特性的多种纳米医药产品来克服这一输送挑战。固体脂质纳米颗粒（SLNs）和纳米结构脂质载体（NLCs）作为口服药物输送纳米药物被引入，可以包封水溶性和脂溶性药物化合物。它们具有生物相容性、生物降解性、毒性和副作用较低、生物利用度、溶解度和渗透性增强、半衰期和稳定性延长以及组织靶向药物输送等特点，使它们在这方面独一无二。© 2023 The Authors.

Brain, predisposed to local and metastasized tumors, has always been the focus of oncological studies. Glioblastoma multiforme (GBM), the most common invasive primary tumor of the brain, is responsible for 4% of all cancer-related deaths worldwide. Despite novel technologies, the average survival rate is 2 years. Physiological barriers such as blood-brain barrier (BBB) prevent drug molecules penetration into brain. Most of the pharmaceuticals present in the market cannot infiltrate BBB to have their maximum efficacy and this in turn imposes a major challenge. This mini review discusses GBM and physiological and biological barriers for anticancer drug delivery, challenges for drug delivery across BBB, drug delivery strategies focusing on SLNs and NLCs and their medical applications in on-going clinical trials. Numerous nanomedicines with various characteristics have been introduced in the last decades to overcome the delivery challenge. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) were introduced as oral drug delivery nanomedicines which can be encapsulated by both hydrophilic and lipophilic pharmaceutical compounds. Their biocompatibility, biodegradability, lower toxicity and side effects, enhanced bioavailability, solubility and permeability, prolonged half-life and stability and finally tissue-targeted drug delivery makes them unique among all.©2023 The Authors.